An update on #covid19 monoclonal antibody distribution, via HHS:
— 993,000 doses shipped to 6,007 sites, as of 6/16
— 533,000 doses reported used since 12/9/20 (a relatively small # of add'l doses may have been used before then)
— 54% of distributed supply used (thru 6/2/2021)
This farewell piece embodies all that I have long admired in @nytDeniseGrady -- beautiful writing, precise and compassionate reporting, and never losing sight of her responsibility to readers or to those who shared their stories. We will miss you, Denise! https://t.co/s5igpyN9fD
Is there a pill we could take to cure Covid-19? The US government is setting up a $3.2 billion program to find out. Here’s my @nytimes story on a major new initiative and why the search for a covid antiviral has been disappointing till now. https://t.co/zEILbycWcW
Get ready for your Covid-19 booster shot! (Maybe.)
Biden administration is buying 200M more doses of Moderna vaccine, with the option to purchase new formulations designed as boosters or pediatric doses. It's not clear whether boosters will be needed.
As the debate over the virus origins raged last week, I picked up the phone & called the Wuhan scientist at the center of the lab leak theories.
To my surprise, she picked up.
More on what Dr. Shi Zhengli, the "Bat Woman," had to say in our profile. https://t.co/1ERbG759fY
Novavax’s big US-Mexico trial confirmed their protein vaccine works well, with 90 percent efficacy. It’s late for the US, but not for the world. And it might prove a good booster too. Here is my story for @nytimeshttps://t.co/YGvfB5QZd7
Scoop: The FDA determined that about 60 million J&J doses made at Emergent BioSolutions can't be used because of contamination risk. The agency plans to allow 10 million doses to be used with a warning about the plant's manufacturing practices. https://t.co/O3g5WrFMAW
The FDA's approval of $BIIB's Aduhelm is spurring major backlash in the scientific community — most notably, with the resignations of 3 advisers to the agency. The question now is whether lawmakers, payers and patients will balk. With @PamBelluck: https://t.co/DSzzLiNBtG
PhRMA CEO pushing back on critcism related to $BIIB approval and pricing. One thing to note is use of word "cure" in 2nd tweet -- the current drug has so far not proven to be anything close to a cure. https://t.co/31gUjFXfzj
This isn’t the first time we’ve heard alarmist predictions about spending on new medicines that were off base. Wildly off base at times. Other dire warnings have missed the mark by an average of 550%. https://t.co/dLj8B73KsA
The Medicare Part B program’s total drug spending was $37 billion in 2019 — roughly equivalent to the budget needed treat only about a third of Americans with mild cognitive problems with Aduhelm. https://t.co/FhVC4JP54s
"A therapy of this cost is going to have enormous implications for everyone. And by everyone, I literally mean you, too. There’s going to be some 60 & 70 yos on your plan. If they start getting this treatment, you will see your premiums go up.” -@jsross119https://t.co/FhVC4JP54s